TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Dermata Therapeutics ( (DRMA) ) has provided an update.
On September 17, 2025, Dermata Therapeutics presented clinical data from its Phase 3 STAR-1 trial of XYNGARI™ at the European Academy of Dermatology and Venereology Congress. The results showed statistically significant improvements in acne treatment outcomes compared to placebo, indicating potential advancements in the company’s dermatological offerings.
The most recent analyst rating on (DRMA) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Dermata Therapeutics stock, see the DRMA Stock Forecast page.
Spark’s Take on DRMA Stock
According to Spark, TipRanks’ AI Analyst, DRMA is a Underperform.
Dermata Therapeutics’ stock is primarily impacted by its financial health, characterized by significant operating losses and reliance on external financing. Technical analysis indicates a bearish trend with potential overselling, while valuation remains difficult to assess due to negative earnings. These factors contribute to a low overall score.
To see Spark’s full report on DRMA stock, click here.
More about Dermata Therapeutics
Dermata Therapeutics, Inc. operates in the biotechnology industry, focusing on the development of novel therapies for dermatological conditions. The company’s primary product, XYNGARI™ (DMT310), is aimed at treating acne, with a significant market focus on dermatology.
Average Trading Volume: 24,111
Technical Sentiment Signal: Sell
Current Market Cap: $3.7M
See more data about DRMA stock on TipRanks’ Stock Analysis page.